Three decades of evolving treatment for melanoma: No improvement in survival?

Authors:

Abstract
7511 Background: Despite tremendous effort towards the development of novel treatments for advanced melanoma, a significant survival benefit has not been clearly documented. The objective of the current study is to determine whether the survival of AJCC stage III melanoma has improved over the past 30 years. Methods: A prospective database of >12,000 melanoma patients was used to identify patients evaluated and treated at our institution within 4 months of an AJCC stage III diagnosis. After exclusion of subjects receiving active specific immunotherapy, patients were assigned to 3 chronologic groups (Table). A computer program matched patients from each group by known prognostic variables (non-palpable/micrometastases vs. palpable/macrometastases nodes, number of metastatic nodes, and pT stage) to randomly create sets of patients. Results: From a cohort of 1,422 patients, 882 were matched into 294 sets. No significant inter-group differences in 5- or 10-year survival were observed (p=0.99). There were no s...